Exchanges: NASDAQ | NYSE | XLON | AMS | ADS | TSE | BRU

Financial News Feed

Stronger Sell Today AMED ranks #3061 as SELL CANDIDATE #3061 Weaker Sell

AMED stock forecast Amedisys Inc

AMED stock forecast

Amedisys (AMED) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).

Read more

Zacks.com featured highlights include: Medifast, Shoe Carnival, Marine Products, Amedisys and NVR

Read more

Zacks.com featured highlights include: Intuit, Insperity, Amedisys, Pioneer Natural and Century Casinos

Read more

Zacks.com featured highlights include: Shoe Carnival, Ulta, Amedisys, NVR and EMCOR

Read more

Amedisys (AMED) is well positioned to outperform the market, as it exhibits above-average growth in financials.

Read more

Amedisys (AMED) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Read more

Amedisys (AMED) could produce exceptional returns because of its solid growth attributes.

Read more

Zacks.com featured highlights include: Exantas Capital, Lamb Weston, Bristol-Myers Squibb, Amedisys and Computer Programs and Systems

Read more

Amedisys, Inc. (NASDAQ:AMED) Q1 2019 Results Conference Call May 01, 2019 11:00 AM ET Company Participants Nick Muscato - Vice President of Strategic Finance Pa

Read more

AMED earnings call for the period ending March 31, 2019.

Read more

Amedisys down 6% after strong quarter
06:28pm, Wednesday, 01'st May 2019
It was a "blowout" quarter, says William Blair bull Matt Larew, with "strength throughout the business and upside on every relevant financial metric." Neve

Read more

Amedisys (AMED) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Read more

Amedisys Q1 2019 Earnings Preview
09:35pm, Monday, 29'th Apr 2019

Read more

Proudly made at

Rise Vilnius
in partnership with
Barclays Bank